Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Mouse IL17F Polyclonal Antibody

Catalog #:   PMJ41201 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q7TNI7
Overview

Catalog No.

PMJ41201

Species reactivity

Mouse

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Mouse IL17F (Ala21-Ala161).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

IL17F, Interleukin-17F, IL-17F, Cytokine ML-1

Purification

Purified by antigen affinity column.

Accession

Q7TNI7

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with IL17F antibody (PMJ41201) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 18 kDa
    Observed MW: 18 kDa
References

Adipose-Derived Mesenchymal Stromal/Stem Cells Reduce Inflammatory Responses and Partially Alleviate Skin Symptoms in Imiquimod-Induced Psoriasis-Like Dermatitis Model Mice., PMID:40500215

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)., PMID:40358828

IL-17A, IL-17F, and IL-23 in Patients with Rheumatoid Arthritis., PMID:40353959

Assessing the clinical progress of the bispecific nanobody sonelokimab., PMID:40297934

Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein., PMID:40152593

Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation., PMID:40127522

Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block., PMID:40076933

Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient., PMID:40016589

Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab., PMID:39978685

Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions., PMID:39946257

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics., PMID:39925216

Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders., PMID:39875232

Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period., PMID:39862230

Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies., PMID:39798135

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study., PMID:39666087

Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children., PMID:39616006

The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples., PMID:39531733

Amelioration of Systemic Amyloidosis by Blocking IL-17A and Not by IL-17F, and Arteriosclerosis by Blocking Both IL-17A and IL-17F in an Inflammatory Skin Mouse Model., PMID:39519167

Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study., PMID:39498997

Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial., PMID:39493888

Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review., PMID:39425925

Bimekizumab for the treatment of hidradenitis suppurativa., PMID:39297706

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., PMID:39215949

Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study., PMID:39133570

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel., PMID:39093660

Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment., PMID:39093648

Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial., PMID:39083288

Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis., PMID:39079980

IL-17A/F double producing T cells, unstable Tregs and quiescent TRMs in clinically healed lesions are potential cellular candidates for recurrence of psoriasis., PMID:39067676

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials., PMID:38977276

Biologics for Psoriasis., PMID:38796266

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials., PMID:38795716

Bimekizumab: A Review in Psoriatic Arthritis., PMID:38703349

Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature., PMID:38673523

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting., PMID:38662223

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland., PMID:38650583

Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis., PMID:38646719

Tumor necrosis factor alpha induced protein 3, interleukin 10, tumor necrosis factor alpha, and interleukin 17 F genes polymorphisms in Algerian patients with rheumatoid arthritis., PMID:38642181

Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders., PMID:38636269

Dual blockade of interleukin-17A and interleukin-17F as a therapeutic strategy for liver fibrosis: Investigating the potential effect and mechanism of brodalumab., PMID:38531177

Bimekizumab for the treatment of psoriasis., PMID:38506262

Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study., PMID:38482898

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials., PMID:38447700

Prevention of experimental autoimmune encephalomyelitis by targeting 6-sulfo sialyl Lewis X glycans involved in lymphocyte homing., PMID:38387051

Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis., PMID:38253404

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis., PMID:38218744

Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)., PMID:38073013

Biomass-related PM2.5 induced inflammatory microenvironment via IL-17F/IL-17RC axis., PMID:38036089

IL-17 receptor A functions to help maintain barrier integrity and limit activation of immunopathogenic response to H. pylori infection., PMID:38014948

Protective role of IL-17-producing γδ T cells in a laser-induced choroidal neovascularization mouse model., PMID:38007487

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Mouse IL17F Polyclonal Antibody [PMJ41201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only